Heparin‑Induced Thrombocytopenia — 4Ts Score, PF4 Testing, and Non‑Heparin Anticoagulation

Key Points

• Use the highest‑yield diagnostic test early; do not let testing delay time‑critical therapy.
• Set objective targets (hemodynamic, neurologic, respiratory) and reassess frequently.
• Plan definitive source control or immunomodulation when indicated; document follow‑up and patient education.

Algorithm

1. Calculate 4Ts score; if low, consider alternate diagnosis and avoid testing.
2. If intermediate/high → stop all heparin immediately; avoid platelet transfusions unless bleeding.
3. Start non‑heparin anticoagulant; send PF4 ELISA ± functional assay (SRA).
4. If confirmed, continue anticoagulation (usually 4–6 weeks if no thrombosis; 3 months if thrombosis).
5. Avoid heparin in future; document allergy and provide patient education.

Clinical Synopsis & Reasoning

Immune‑mediated thrombocytopenia with thrombosis risk 5–10 days after heparin exposure. Use 4Ts score for pretest probability, stop all heparin, send PF4 immunoassay with functional testing as needed, and start a non‑heparin anticoagulant while awaiting confirmatory testing.

Treatment Strategy & Disposition

Stabilize ABCs. Initiate guideline‑concordant first‑line therapy with precise dosing and continuous monitoring. Escalate to advanced or procedural interventions based on explicit failure criteria. Define ICU, step‑down, and ward disposition triggers; involve specialty teams early.

Epidemiology / Risk Factors

• Risk varies by comorbidity and precipitants; see citations for condition‑specific data.

Investigations

Pharmacology

Prognosis / Complications

• Outcome depends on timeliness of diagnosis and definitive therapy; monitor for complications.

Patient Education / Counseling

• Provide red‑flag education, adherence guidance, and explicit return precautions; arrange timely specialty follow‑up.

References

1. ASH Clinical Practice Guidelines for HIT (2018) + Pocket Guide — Link